Managing Patients with T1D Update
Managing Patients with T1D Update
This activity is available to fellowship training programs subscribed to the Fellows Training Series.
Managing patients type 1 diabetes (T1D) and the associated complications using patient-centered care and evolving therapies requires continual education for endocrine fellows, especially during a time of increasing endocrinologist workforce needs. This activity consists of 6 topic-specific modules relating to T1D care and management. Each module consists of a recorded presentation from the "Endocrine Fellows Series: Type 1 Diabetes Care and Management" conferences and clinical case vignettes with answer rationales and references. The topic-specific modules are:
- Mental Health
- Insulin Pump Therapy
- DKA Management
- Inpatient Management
This continuing medical education activity should be of substantial interest to pediatric and adult endocrine fellows.
Upon completion of this educational activity, participants will be able to (or better able to):
- Devise individualized treatment strategies to manage individuals with T1D with and without common comorbid conditions
- Incorporate insulin pump therapy into treatment strategies for appropriate individuals with T1D
- Recognize and evaluate individuals with T1D for signs of depression and distress
- Apply updated knowledge of treatments, practice guidelines, and clinical skills to improve care, long-term outcomes, and DKA management of individuals with T1D
Alan C. Dalkin, MD, University of Virginia Health System
Irl B. Hirsch, MD, University of Washington Sch of Med
Linda M. Siminerio, RN, PhD, CDE, University of Pittsburgh Diabetes Institute
Jean Pujals-Kury, MD, SUNY Downstate Medical Center
Elizabeth Seaquist, MD, University of Minnesota
Michael C. Riddell, PhD, York University
Jill A. Weissberg-Benchell, PhD, CDE, Northwestern University
Janet McGill, MD, MA, FACE, Washington University in St. Louis
Guillermo E. Umpierrez, MD, CDE, Emory University
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Irl B. Hirsch, MD, has served as a consultant to Abbott Diabetes Care; Becton, Dickinson and Company; Bigfoot Biomedical, Inc.; and Roche; and has received research support from Medtronic Diabetes.
Janet B. McGill, MD, has served as a consultant to Bayer, Gilead, Novo Nordisk Inc., and Sanofi; has received research support from Dexcom, Jaeb Center for Health Research, Medtronic, Novartis, and Sanofi; has served as a speaker for Aegerion, Dexcom, Janssen, and Mannkind.
Michael C. Riddell, PhD, has served as an advisory board member and/or speaker for Ascensia Diabetes Care, Eli Lilly and Company, Insulet Corporation, Medtronic; received grant support from Insulet Corporation; and received research support from Novo Nordisk and Sanofi.
Elizabeth Seaquist, MD, has served as an advisor to Eli Lilly and Company; has served as a consultant to Eli Lilly and Company, Mannkind Corporation, Sanofi, and Zucara; has received research support from Eli Lilly and Company; and has served as a sponsor of the International Hypoglycemia Study Group supported by Novo Nordisk Inc.
Guillermo E. Umpierrez, MD, CDE, has received support that was provided to his institution by AstraZeneca, Dexcom, Merck, Novo Nordisk, and Sanofi; and has served as an advisory board member to AstraZeneca and Janssen.
The following faculty reported no relevant financial relationship: Alan C. Dalkin, MD, Jean Pujals-Kury, MD; Linda M. Siminerio, RN, PhD, CDE; and Jill A. Weissberg-Benchell, PhD, CDE.
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by a grant from the following supporters: Abbott Diabetes Care Inc.; Dexcom, Inc.; The Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novo Nordisk Inc.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this enduring activity for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Review your Diplomate ABIM ID Number(s)
In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:
- Provide your board-certification information in your educational profile. Your profile currently contains the following board ID numbers (must be logged in to view):
Your ABIM Number: [current-user:profile-profile:field-number-abim]*
*If your ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.
- 12.00 ABIM MOC
- 12.00 AMA PRA Category 1 Credits™
- 12.00 CME Certificate of Participation